Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan plus 5-FU/LV in Stage III Colon Cancer
NCT00003835Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- May 1999
- Primary completion
- Aug 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colon cancer, sponsored by National Cancer Institute. Primary endpoints: Disease Free Survival at 6 years and Overall Survival at 6 years. Started May 1999; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00003835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003835.